IP Library Granted Patent US 8,299,243
Granted Patent B2
US 8,299,243 · App. 13/248,446 · Granted Oct 30, 2012

Indazole, benzisoxazole, and benzisothiazole kinase inhibitors

Assignee: AbbVie Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,299,243
App. No.
13/248,446
Granted
Oct 30, 2012
Kind
B2
Abstract

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Claims (110)

1. A compound of formula (I)

or a therapeutically acceptable salt thereof, wherein

A is phenyl;

X is NR 9 ;

one of R 1 and R 2 is hydrogen and the other is selected from the group consisting of aryloxyalkyl, heterocyclyl, heterocyclylalkenyl, heterocyclylalkoxy, heterocyclylalkyl, heterocyclyloxyalkyl, (NR a R b )alkoxy, (NR a R b )alkenyl, (NR a R b )alkyl, (NR a R b )alkynyl, (NR a R b )carbonylalkenyl, and (NR a R b )carbonylalkyl;

R 3 and R 4 are each independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkyl, halo, haloalkoxy, haloalkyl, and hydroxy;

R 5 is LR 6 ;

L is selected from the group consisting of (CH 2 ) m N(R 7 )C(O)N(R 8 )(CH 2 ) n and CH 2 C(O)NR 7 , wherein m is 0 and n is 0, and wherein each group is drawn with its left end attached to A;

R 6 is selected from the group consisting of hydrogen, aryl, cycloalkyl, heterocyclyl, and 1,3-benzodioxolyl wherein the 1,3-benzodioxolyl can be optionally substituted with one, two, or three substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, aryl, arylalkoxy, arylalkyl, aryloxy, carboxy, cyano, cycloalkyl, halo, haloalkoxy, haloalkyl, a second heterocyclyl group, heterocyclylalkyl, hydroxy, hydroxyalkyl, nitro, —NR c R d , and (NR c R d )alkyl;

R 7 and R 8 are independently selected from the group consisting of hydrogen and alkyl;

R 9 is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkylcarbonyl, aryl, heterocyclylalkyl, hydroxyalkyl, and (NR a R b )alkyl;

R a and R b are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylcarbonyl, arylsulfonyl, haloalkylsulfonyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, and heterocyclylsulfonyl; and

R c and R d are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl and heterocyclyl.

2. The compound of claim 1 of formula (II)

or a therapeutically acceptable salt thereof, wherein

X is NR 9 ;

one of R 1 and R 2 is hydrogen and the other is selected from the group consisting of aryloxyalkyl, heterocyclyl, heterocyclylalkenyl, heterocyclylalkoxy, heterocyclylalkyl, heterocyclyloxyalkyl, (NR a R b )alkoxy, (NR a R b )alkenyl, (NR a R b )alkyl, (NR a R b )carbonylalkenyl, and (NR a R b )carbonylalkyl;

R 3 and R 4 are independently selected from the group consisting of hydrogen, alkoxy, alkyl, halo, haloalkoxy, haloalkyl, and hydroxy;

L is selected from the group consisting of (CH 2 ) m N(R 7 )C(O)N(R 8 )(CH 2 ) n and CH 2 C(O)NR 7 , wherein m is 0 and n is 0, and wherein each group is drawn with its left end attached to the ring substituted with R 3 and R 4 ;

R 7 and R 8 are independently selected from the group consisting of hydrogen and alkyl;

R 9 is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkylcarbonyl, aryl, heterocyclylalkyl, hydroxyalkyl, and (NR a R b )alkyl;

R 10 and R 11 are independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy, arylalkyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and —NR c R d ;

R a and R b are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; and

R c and R d are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl.

3. The compound of claim 2 wherein L is (CH 2 ) m N(R 7 )C(O)N(R 8 )(CH 2 ) n .

4. The compound of claim 3 wherein R 7 and R 8 are hydrogen, and R 9 is hydrogen.

5. The compound of claim 4 wherein one of R 1 and R 2 is hydrogen and the other is heterocyclylalkoxy.

6. The compound of claim 5 selected from the group consisting of

N-(4-{3-amino-7-[2-(4-morpholinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-(3-methylphenyl)urea;

N-(4-{3-amino-7-[2-(4-morpholinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-phenylurea;

N-(4-{3-amino-7-[2-(4-morpholinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-(3-fluorophenyl)urea;

N-(4-{3-amino-7-[2-(4-morpholinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N-(3-bromophenyl)urea;

N-(4-{3-amino-7-[2-(4-morpholinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N-(3-ethylphenyl)urea;

N-(4-{3-amino-7-[2-(4-morpholinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-[2-fluoro-5-(trifluoromethyl)phenyl]urea;

N-(4-{3-amino-7-[2-(4-morpholinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-[4-fluoro-3-(trifluoromethyl)phenyl]urea;

N-(4-{3-amino-7-[2-(4-morpholinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N-(3-chlorophenyl)urea;

N-(4-{3-amino-7-[2-(4-morpholinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-[3-(trifluoromethyl)phenyl]urea;

N-(4-{3-amino-7-[2-(2-oxo-1-pyrrolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-(3-methylphenyl)urea;

N-(4-{3-amino-7-[2-(2-oxo-1-pyrrolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N-(3-chlorophenyl)urea;

N-(4-{3-amino-7-[2-(4-morpholinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-(2-fluoro-5-methylphenyl)urea;

N-(4-{3-amino-7-[2-(1-pyrrolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-phenylurea;

N-(4-{3-amino-7-[2-(1-pyrrolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-(3-fluorophenyl)urea;

N-(4-{3-amino-7-[2-(1-pyrrolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-(2-fluoro-5-methylphenyl)urea;

N-(4-{3-amino-7-[2-(1-pyrrolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-(3-methylphenyl)urea;

N-(4-{3-amino-7-[2-(1-pyrrolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N-(3-bromophenyl)urea;

N-(4-{3-amino-7-[2-(1-pyrrolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-[2-fluoro-5-(trifluoromethyl)phenyl]urea;

N-(4-{3-amino-7-[2-(1-pyrrolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-(3-chlorophenyl)urea;

N-(4-{3-amino-7-[2-(1-pyrrolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-[3-(trifluoromethyl)phenyl]urea;

N-(4-{3-amino-7-[2-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-(3-methylphenyl)urea;

N-(4-{3-amino-7-[2-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-(3-chlorophenyl)urea;

N-(4-{3-amino-7-[2-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-(2-fluoro-5-methylphenyl)urea;

N-(4-{3-amino-7-[2-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-[3-(trifluoromethyl)phenyl]urea;

N-(4-{3-amino-7-[2-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)ethoxy]-1H-indazol-4-yl}phenyl)-N′-(3,5-dimethylphenyl)urea;

N-{4-[3-amino-7-(3-morpholin-4-ylpropoxy)-1H-indazol-4-yl}phenyl)-N′-pheny]urea;

N-(4-{3-amino-7-(3-morpholin-4-ylpropoxy)-1H-indazol-4-yl}phenyl)-N′-(3-fluorophenyl)urea;

N-(4-{3-amino-7-(3-morpholin-4-ylpropoxy)-1H-indazol-4-yl}phenyl)-N′-(2-fluoro-5-methylphenyl)urea;

N-{-4-[3-amino-7-(3-morpholin-4-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-(3-methylphenyl)urea;

N-{4-[3-amino-7-(3-morpholin-4-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-[2-fluoro-5-(trifluoromethyl)phenyl]urea;

N-{-4-[3-amino-7-(3-morpholin-4-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-(3-chlorophenyl)urea;

N-{-4-[3-amino-7-(3-morpholin-4-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-[3-(trifluoromethyl)phenyl]urea;

N-(4-{3-amino-7-[3-(1H-pyrrol-1-yl)propoxy]-1H-indazol-4-yl}phenyl)-N′-(2-fluoro-5-methylphenyl)urea;

N-(4-{3-amino-7-[3-(1H-pyrrol-1-yl)propoxy]-1H-indazol-4-yl}phenyl)-N′-(3-methylphenyl)urea;

N-(4-{3-amino-7-[3-(1H-pyrrol-1-yl)propoxy]-1H-indazol-4-yl}phenyl)-N′-(3-chlorophenyl)urea;

N-{-4-[3-amino-7-(3-morpholin-4-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-(3-bromophenyl)urea;

N-(4-{3-amino-7-[(1-methylpiperidin-4-yl)methoxy]-1H-indazol-4-yl}-2-fluorophenyl)-N′-(2-fluoro-5-methylphenyl)urea;

N-(4-{3-amino-7-[(1-methylpiperidin-4-yl)methoxy]-1H-indazol-4-yl}phenyl)-N′-(3-methylphenyl)urea;

N-(4-{3-amino-7-[(1-methylpiperidin-4-yl)methoxy]-1H-indazol-4-yl}phenyl)-N′-(3-chlorophenyl)urea;

N-(4-{3-amino-7-[(1-methylpiperidin-4-yl)methoxy]-1H-indazol-4-yl}phenyl)-N′-(4-fluoro-3-methylphenyl)urea;

N-{4-[3-amino-7-(3-pyridin-3-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-(3-chlorophenyl)urea;

N-{4-[3-amino-7-(3-pyridin-3-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-(3-methylphenyl)urea;

N-{4-[3-amino-7-(3-pyridin-3-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-[4-fluoro-3-(trifluoromethyl)phenyl]urea;

N-{-4-[3-amino-7-(3-pyridin-3-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-(4-fluoro-3-methylphenyl)urea;

N-{-4-[3-amino-7-(3-pyridin-3-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-(3-chloro-4-fluorophenyl)urea;

N-{-4-[3-amino-7-(3-pyridin-3-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-[3-(trifluoromethyl)phenyl]urea;

N-{-4-[3-amino-7-(3-pyridin-4-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-(2-fluoro-5-methylphenyl)urea;

N-{-4-[3-amino-7-(3-pyridin-4-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-(3-methylphenyl)urea;

N-{-4-[3-amino-7-(3-pyridin-4-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-(3-chlorophenyl)urea; and

N-{-4-[3-amino-7-(3-pyridin-3-ylpropoxy)-1H-indazol-4-yl]phenyl}-N′-(2-fluoro-5-methylphenyl)urea.

7. The compound of claim 4 wherein one of R 1 and R 2 is hydrogen and the other is selected from the group consisting of aryloxyalkyl, heterocyclyl, heterocyclylalkyl, and heterocyclyloxyalkyl.

8. The compound of claim 7 selected from the group consisting of

N-{-4-[3-amino-7-(4-morpholinylmethyl)-1H-indazol-4-yl]phenyl}-N′-(3-fluorophenyl)urea;

N-{-4-[3-amino-7-(4-morpholinylmethyl)-1H-indazol-4-yl]phenyl}-N′-(3-methylphenyl)urea;

N-{-4-[3-amino-7-(4-morpholinylmethyl)-1H-indazol-4-yl]phenyl}-N′-[2-fluoro-5-(trifluoromethyl)phenyl]urea;

N-{-4-[3-amino-7-(4-morpholinylmethyl)-1H-indazol-4-yl]phenyl}-N′-[4-fluoro-3-(trifluoromethyl)phenyl]urea;

N-{-4-[3-amino-7-(4-morpholinylmethyl)-1H-indazol-4-yl]phenyl}-N′-[3-(trifluoromethyl)phenyl]urea;

N-(4-{3-amino-7-[(4-methyl-1-piperazinyl)methyl]-1H-indazol-4-yl}phenyl)-N′-(3-chlorophenyl)urea;

N-(4-{3-amino-7-[(4-methyl-1-piperazinyl)methyl]-1H-indazol-4-yl}phenyl)-N′-(3-methylphenyl)urea;

N-(4-{3-amino-7-[(4-methyl-1-piperazinyl)methyl]-1H-indazol-4-yl}phenyl)-N′-(3-fluorophenyl)urea;

N-(4-{3-amino-7-[(4-methyl-1-piperazinyl)methyl]-1H-indazol-4-yl}phenyl)-N′-[3-(trifluoromethyl)phenyl]urea;

N-(4-{3-amino-7-[(4-methyl-1-piperazinyl)methyl]-1H-indazol-4-yl}phenyl)-N′-[2-fluoro-5-(trifluoromethyl)phenyl]urea;

N-(4-{3-amino-7-[(4-methyl-1-piperazinyl)methyl]-1H-indazol-4-yl}phenyl)-N′-(2-fluoro-5-methylphenyl)urea;

N-(4-{3-amino-7-[(3-pyridinyloxy)methyl]-1H-indazol-4-yl}phenyl)-N′-[3-(trifluoromethyl)phenyl]urea;

N-(4-{3-amino-7-[(4-chlorophenoxy)methyl]-1H-indazol-4-yl}phenyl)-N′-(2-fluoro-5-methylphenyl)urea;

N-(4-{3-amino-7-[(4-chlorophenoxy)methyl]-1H-indazol-4-yl}phenyl)-N-(3-chlorophenyl)urea;

N-(4-{3-amino-7-[(4-chlorophenoxy)methyl]-1H-indazol-4-yl}phenyl)-N′-[3-(trifluoromethyl)phenyl]urea;

N-(4-{3-amino-7-[(4-chlorophenoxy)methyl]-1H-indazol-4-yl}phenyl)-N′-(3-methylphenyl)urea;

N-(4-{3-amino-7-[(4-chlorophenoxy)methyl]-1H-indazol-4-yl}phenyl)-N′-(4-fluoro-3-methylphenyl)urea;

N-[4-(3-amino-7-pyridin-3-yl-1H-indazol-4-yl)phenyl]-N′-(4-fluoro-3-methylphenyl)urea;

N-[4-(3-amino-7-pyridin-3-yl-1H-indazol-4-yl)phenyl]-N′-(3-chlorophenyl)urea;

N-[4-(3-amino-7-pyridin-3-yl-1H-indazol-4-yl)phenyl]-N′-[3-(trifluoromethyl)phenyl]urea;

N-[4-(3-amino-7-pyridin-3-yl-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea;

N-[4-(3-amino-7-pyridin-3-yl-1H-indazol-4-yl)phenyl]-N′-[4-fluoro-3-(trifluoromethyl)phenyl]urea;

N-[4-(3-amino-7-thien-3-yl-1H-indazol-4-yl)phenyl]-N′-[3-(trifluoromethyl)phenyl]urea;

N-[4-(3-amino-7-thien-3-yl-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea;

N-[4-(3-amino-7-pyridin-4-yl-1H-indazol-4-yl)phenyl]-N′-(4-fluoro-3-methylphenyl)urea;

N-[4-(3-amino-7-pyridin-4-yl-1H-indazol-4-yl)phenyl]-N′-[3-(trifluoromethyl)phenyl]urea;

N-[4-(3-amino-7-pyridin-4-yl-1H-indazol-4-yl)phenyl]-N′-(3-chlorophenyl)urea;

N-[4-(3-amino-7-pyridin-4-yl-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea;

N-[4-(3-amino-7-pyridin-4-yl-1H-indazol-4-yl)phenyl]-N′-[4-fluoro-3-(trifluoromethyl)phenyl]urea; and

N-[4-(3-amino-7-pyridin-4-yl-1H-indazol-4-yl)phenyl]-N′-[2-fluoro-5-(trifluoromethyl)phenyl]urea.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030176/0968 →
Continuity (5)
Division 12507575 · Jul 22, 2009
Continuation 11867887 · Oct 5, 2007
Division 10842292 · May 10, 2004
Provisional Application 60472810 · May 22, 2003
Related Publication 20120022253A1 · Jan 26, 2012